Skip to main content
. 2018 Sep 14;22(12):6015–6025. doi: 10.1111/jcmm.13874

Figure 5.

Figure 5

Schematic detailing molecular mechanisms behind combination pFUS and mesenchymal stromal cells (MSC) therapy in cisplatin AKI. Following cisplatin infusion and establishment of AKI, pFUS up‐regulates renal IFNγ which stimulates subsequently infused MSC to up‐regulate IL‐10 and promote AKI healing